Insights into innovative therapeutics for drug-resistant tuberculosis: Host-directed therapy and autophagy inducing modified nanoparticles

Simple item page
dc.contributor.authorKhoza, Leon J.
dc.contributor.authorKumar, Pradeep
dc.contributor.authorDube, Admire
dc.date.accessioned2022-07-11T11:52:51Z
dc.date.available2022-07-11T11:52:51Z
dc.date.issued2022
dc.description.abstractTuberculosis (TB) remains one of the deadliest communicable dis- eases caused by Mycobacterium tuberculosis (Mtb) since its discovery in the 1880s (Cambau and Drancourt, 2014; Singh et al., 2020). Over 1 billion mortalities have been recorded to date due to TB, and it was the leading cause of death from a single infectious agent before the COVID- 19 pandemic, with an estimated 10.4 million new cases and an average of 1.7 million deaths yearly (Gagneux, 2018; Barberis et al., 2017; Scriba et al., 2020; Allu ́e-Guardia et al., 2021; Organization, 2021). Further, about 25% of the world’s population are latently ill or infected, providing a substantial pool for future cases of active TB (Gagneux, 2018). The World Health Organisation (WHO) reported that in 2019 an average of 10 million new cases were recorded, with 1.2 million cases being children and an estimated total of 1.4 million mortalities (Orga- nization, 2019).en_US
dc.identifier.citationKhoza, L. J. et al. (2022). Insights into innovative therapeutics for drug-resistant tuberculosis: Host-directed therapy and autophagy inducing modified nanoparticles. International Journal of Pharmaceutics, 622,121893. https://doi.org/10.1016/j.ijpharm.2022.121893en_US
dc.identifier.issn0378-5173
dc.identifier.urihttps://doi.org/10.1016/j.ijpharm.2022.121893
dc.identifier.urihttp://hdl.handle.net/10566/7583
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.subjectTuberculosisen_US
dc.subjectNanoparticlesen_US
dc.subjectAlveolar macrophagesen_US
dc.subjectMycobacterium tuberculosisen_US
dc.subjectTherapeuticsen_US
dc.titleInsights into innovative therapeutics for drug-resistant tuberculosis: Host-directed therapy and autophagy inducing modified nanoparticlesen_US
dc.typeArticleen_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
khoza_insights into innovative therapeutics for drug-resistant tuberculosis_2022.pdf
Size:
5.85 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Research Articles (School of Pharmacy)